Skip to main content

ENTA

Stock
Health Care
Biotechnology

Performance overview

ENTA Price
Price Chart

Forward-looking statistics

Beta
1.60
Risk
74.97%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Company info

SectorHealth Care
IndustryBiotechnology
Employees151
Market cap$273.4M

Fundamentals

Enterprise value$184.4M
Revenue$64.5M
Revenue per employee—
Profit margin-149.57%
Debt to equity231.07

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$4.53
Dividend per share—
Revenue per share$3.04
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$1M
Put-call ratio—

Macro factor sensitivity

Growth+2.3
Credit+1.7
Liquidity+0.8
Inflation-0.5
Commodities+0.3
Interest Rates-1.9

Valuation

Dividend yield0.00%
PEG Ratio-1.64
Price to sales2.62
P/E Ratio-1.64
Enterprise Value to Revenue2.86
Price to book1.80

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?

The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research (May 15, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free